Allogene Therapeutics, Inc. Contracts & Agreements

Amendment No. 1 to (Filed With SEC on August 7, 2024)

Amendment No. 1 to Amended and Restated Collaboration and License Agreement, dated May 17, 2024, by and between Allogene Therapeutics, Inc. and Notch Therapeutics (Canada) Inc (Filed With SEC on August 7, 2024)

Amendment and Settlement Agreement, dated May 10, 2024, by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier and Allogene Therapeutics, Inc (Filed With SEC on August 7, 2024)

First Amendment to the License Agreement, dated May 24, 2024, by and between Allogene Therapeutics Inc. and Allogene Overland BioPharm (PRC) Co., Limited (Filed With SEC on August 7, 2024)

Amended and (Filed With SEC on August 7, 2024)

Share Exchange Agreement, dated May 24, 2024, by and (Filed With SEC on August 7, 2024)

Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated May 13, 2024 (Filed With SEC on May 14, 2024)

Underwriting Agreement by and between the Company and Goldman Sachs & Co. LLC, dated May 13, 2024 (Filed With SEC on May 14, 2024)

Non-employee director compensation policy, as amended (Filed With SEC on May 13, 2024)

Non-Employee Director Compensation Policy (Filed With SEC on March 14, 2024)

First Amendment to Consulting Agreement, dated December 16, 2023, by and between the Registrant and Alison Moore, Ph.D (Filed With SEC on March 14, 2024)

Amended and Restated Collaboration and License Agreement, dated January 17, 2024, by and between the Registrant and Notch Therapeutics Inc (Filed With SEC on March 14, 2024)

Strategic Collaboration Agreement, dated January 3, 2024, by and between Foresight Diagnostics, Inc. and the Registrant (Filed With SEC on March 14, 2024)

Employment Letter of Agreement, dated August 11, 2023, by and between the Registrant and Earl Douglas (Filed With SEC on November 2, 2023)

Employment Letter of Agreement, dated October 12, 2023, by and between the Registrant and Geoffrey Parker (Filed With SEC on November 2, 2023)

Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Filed With SEC on November 2, 2023)

Amendment No. 2 to Sales Agreement, dated November 2, 2023, by and between the Registrant and Cowen and Company, LLC (Filed With SEC on November 2, 2023)

Employment Letter of Agreement, dated April 18, 2023, by and between the Registrant and Timothy Moore (Filed With SEC on May 3, 2023)

Consulting Agreement, dated April 29, 2023, by and between the Registrant and Alison Moore, Ph.D (Filed With SEC on May 3, 2023)

Consulting Agreement, dated April (Filed With SEC on May 3, 2023)

Employment Letter of Agreement, dated December 28, 2022, by and between the Registrant and Zachary Roberts, M.D., Ph.D (Filed With SEC on February 28, 2023)

Description of Common Stock (Filed With SEC on February 28, 2023)

First Amendment to the Share Purchase Agreement, dated May 11, 2022, by and among the Registrant, Overland Pharmaceuticals (CY) Inc. and Allogene Overland Biopharm (CY) Limited (Filed With SEC on August 9, 2022)

First Amendment, dated December 10, 2021, to the Lease Agreement, dated October 25, 2018, by and between the Registrant and Healthpeak Properties, Inc. (formerly known as HCP,... (Filed With SEC on February 23, 2022)

First Amendment, dated December 10, 2021, to the Lease, dated August 1, 2018, by and between the Registrant and Britannia Pointe Grand Limited Partnership (Filed With SEC on February 23, 2022)

Shareholders' Agreement, dated December 14, 2020, by and among the Registrant, Overland Pharmaceuticals (CY) Inc. and Allogene Overland Biopharm (CY) Limited (Filed With SEC on February 25, 2021)

Share Purchase Agreement, dated December 14, 2020, by and among the Registrant, Overland Pharmaceuticals (CY) Inc. and Allogene Overland Biopharm (CY) Limited (Filed With SEC on February 25, 2021)

Exclusive License Agreement, dated December 14, 2020, by and between the Registrant and Allogene Overland Biopharm (CY) Limited (Filed With SEC on February 25, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2021)

Second Amendment, dated July 15, 2020, to the Lease Agreement, dated February 19, 2019, by and between the Registrant and Silicon Valley Gateway Technology Center, LLC (Filed With SEC on August 5, 2020)

Underwriting Agreement, dated June 1, 2020, by and among Goldman Sachs & Co. LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named... (Filed With SEC on June 4, 2020)

Employment Letter of Agreement, dated April 30, 2018, by and between the Registrant and Veer Bhavnagri (Filed With SEC on May 6, 2020)

Description of Common Stock (Filed With SEC on February 27, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on February 27, 2020)

Employment Letter of Agreement, dated July 29, 2019, by and between the Registrant and Rafael G. Amado, M.D (Filed With SEC on February 27, 2020)

Collaboration and License Agreement, dated November 1, 2019, by and between the Registrant and Notch Therapeutics Inc (Filed With SEC on February 27, 2020)

First Amendment, dated September 4, 2019, to the Lease Agreement, dated February 19, 2019, by and between the Registrant and Silicon Valley Gateway Technology Center, LLC (Filed With SEC on November 5, 2019)

Lease Agreement, dated October 25, 2018, by and between the Registrant and HCP, Inc (Filed With SEC on March 8, 2019)

Lease Agreement, dated February 19, 2019, by and between the Registrant and Silicon Valley Gateway Technology Center, LLC (Filed With SEC on March 8, 2019)

Allogene Therapeutics, Inc. 2018 Change in Control Plan and Severance Benefit Plan (Filed With SEC on October 2, 2018)

Form of Underwriting Agreement (Filed With SEC on October 2, 2018)

Form of Common Stock Certificate of the Registrant (Filed With SEC on October 2, 2018)

Form of Indemnity Agreement by and between the Registrant and its directors and officers (Filed With SEC on October 2, 2018)

Indemnification Agreement, dated April 6, 2018, by and between the Registrant and John DeYoung (Filed With SEC on October 2, 2018)

Allogene Therapeutics, Inc. Amended and Restated 2018 Equity Incentive Plan and Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, Restricted Stock Unit... (Filed With SEC on October 2, 2018)

Allogene Therapeutics, Inc. 2018 Employee Stock Purchase Plan (Filed With SEC on October 2, 2018)

Non-Employee Director Compensation Policy (Filed With SEC on October 2, 2018)

Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Filed With SEC on October 2, 2018)

Exclusive License and Collaboration Agreement, dated October 30, 2015, by and between the Registrant (assignee of Pfizer Inc.) and Les Laboratoires Servier and Institut de... (Filed With SEC on September 17, 2018)

Transition Services Agreement, dated April 6, 2018, by and between the Registrant and Pfizer Inc (Filed With SEC on September 14, 2018)

Investors Rights Agreement, dated April 6, 2018, by and among the Registrant and certain of its securityholders, as amended September 5, 2018 (Filed With SEC on September 14, 2018)

Allogene Therapeutics, Inc. Amended and Restated 2018 Equity Incentive Plan (Prior Plan) and Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise and Early... (Filed With SEC on September 14, 2018)

Research Collaboration and License Agreement, dated June 17, 2014, by and between the Registrant (assignee of Pfizer Inc.) and Cellectis SA, as amended (Filed With SEC on September 14, 2018)

Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Filed With SEC on September 14, 2018)

Employment Agreement by and between the Registrant and Alison Moore, Ph.D (Filed With SEC on September 14, 2018)

Employment Agreement by and between the Registrant and Eric Schmidt, Ph.D (Filed With SEC on September 14, 2018)

Employment Agreement by and between the Registrant and David Chang, M.D., Ph.D (Filed With SEC on September 14, 2018)

Lease, dated August 1, 2018, by and between the Registrant and Britannia Pointe Grand Limited Partnership (Filed With SEC on September 14, 2018)

Option for Rights to Retained Territory Letter Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Filed With SEC on September 14, 2018)

Category

Industry

Companies

Contracts

Allogene Therapeutics, Inc. Contracts & Agreements